U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 209 results

Status:
US Approved Rx (2014)
First approved in 2014

Class (Stereo):
CHEMICAL (ABSOLUTE)



Olodaterol is a beta2-adrenoceptor agonist discovered by Boehringer Ingelheim and approved for the treatment of Chronic Obstructive Pulmonary Disease. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors af...
Status:
US Approved Rx (2021)
First approved in 2006

Class (Stereo):
CHEMICAL (ABSOLUTE)



Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral canters and is being developed as an inhaled preparation for the treatm...
Status:
US Approved Rx (2022)
First approved in 2001

Class (Stereo):
CHEMICAL (RACEMIC)



Formoterol is a long-acting selective beta2-adrenergic receptor agonist (beta2-agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater agonist acti...
Status:
US Approved Rx (2024)
First approved in 1999

Class (Stereo):
CHEMICAL (ABSOLUTE)



Levalbuterol is the (R)-enantiomer of the drug substance racemic albuterol (salbutamol). Binding studies have demonstrated that (R)-albuterol binds to the beta2-adrenergic receptor with a high affinity, whereas (S)-albuterol binds with 100-fold less ...
Status:
US Approved Rx (2000)
First approved in 1994

Class (Stereo):
CHEMICAL (RACEMIC)



Salmeterol is a long-acting beta2-adrenergic agonist. Although beta2-adrenoceptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-adrenoceptors are the predominant receptors in the heart, there are also beta2-adrenocept...
Status:
US Approved Rx (2003)
First approved in 1992

Class (Stereo):
CHEMICAL (RACEMIC)



Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2...
Status:
US Approved Rx (2000)
First approved in 1988

Class (Stereo):
CHEMICAL (RACEMIC)



Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be u...
Status:
US Approved Rx (1985)
First approved in 1985

Class (Stereo):
CHEMICAL (ABSOLUTE)



Levobunolol is a non-cardioselective beta-adrenoceptor blocking agent, equipotent at both beta1 and beta2 adrenergic receptors. Levobunolol is greater than 60 times more potent than its dextro isomer in its beta-blocking activity, yet equipotent in i...
Status:
US Approved Rx (2009)
First approved in 1985

Class (Stereo):
CHEMICAL (RACEMIC)



Betaxolol or SL 75212, (± )-1-(isopropylamino)-3-(p-(cyclopropylmethoxyethyl-phenoxy)2-propranol, is a potent cardioselective beta1-adrenoceptor antagonist devoid of intrinsic sympathomimetic activity with very weak local anaesthetic properties. Oral...
Status:
US Approved Rx (1984)
First approved in 1981

Class (Stereo):
CHEMICAL (RACEMIC)



Atenolol is a Beta-1 cardio-selective adreno-receptor blocking agent discovered and developed by ICI in 1976. Atenolol was launched in the market under the trade name Tenormin in 1976, and became the best-selling Beta-blocker in the world in the 1980...